Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Patient preferences for different severities of and treatments for overactive bladder.

Wu JM, Fulton RG, Amundsen CL, Knight SK, Kuppermann M.

Female Pelvic Med Reconstr Surg. 2011 Jul;17(4):184-9. doi: 10.1097/SPV.0b013e318223c8ad.

PMID:
22453849
2.
3.

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.

Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.

Curr Med Res Opin. 2009 Sep;25(9):2159-65. doi: 10.1185/03007990903103279.

PMID:
19601704
4.

What is the effect of overactive bladder symptoms on woman's quality of life during and after first pregnancy?

Van Brummen HJ, Bruinse HW, Van de Pol G, Heintz AP, Van der Vaart CH.

BJU Int. 2006 Feb;97(2):296-300.

5.

An overview of treatment of overactive bladder syndrome in women.

Allahdin S, Oo N.

J Obstet Gynaecol. 2012 Apr;32(3):217-21. doi: 10.3109/01443615.2011.649317. Review.

PMID:
22369391
6.
7.

Women's experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups.

Anger JT, Nissim HA, Le TX, Smith AL, Lee U, Sarkisian C, Litwin MS, Raz S, Rodriguez LV, Maliski SL.

Neurourol Urodyn. 2011 Sep;30(7):1295-9. doi: 10.1002/nau.21004. Epub 2011 Apr 28.

8.

Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.

Garely AD, Lucente V, Vapnek J, Smith N.

Ann Pharmacother. 2007 Mar;41(3):391-8. Epub 2007 Mar 6.

PMID:
17341526
9.

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP Jr, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.

Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.

PMID:
19014833
10.

Overactive bladder--a practical approach to evaluation and management.

Madersbacher H.

J Med Liban. 2004 Oct-Dec;52(4):220-6. Review.

PMID:
16432986
11.

Refractory overactive bladder: Beyond oral anticholinergic therapy.

Glinski RW, Siegel S.

Indian J Urol. 2007 Apr;23(2):166-73. doi: 10.4103/0970-1591.32069.

12.

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.

Wagg A, Wyndaele JJ, Sieber P.

Am J Geriatr Pharmacother. 2006 Mar;4(1):14-24.

PMID:
16730617
13.

Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B.

J Urol. 2006 Jul;176(1):177-85.

PMID:
16753396
14.

Sacral neuromodulation in overactive bladder: a review and current perspectives.

Sukhu T, Kennelly MJ, Kurpad R.

Res Rep Urol. 2016 Oct 26;8:193-199. eCollection 2016. Review.

15.

[Update on the second line management of idiopathic overactive bladder].

Chartier-Kastler E, Castro-Diaz D, De Ridder D, Everaert K, Sievert KD, Spinelli M, van Kerrebroeck P.

Prog Urol. 2009 Sep;19(8):530-7. doi: 10.1016/j.purol.2009.02.001. Epub 2009 Mar 19. Review. French.

PMID:
19699450
16.

Understanding the elements of overactive bladder: questions raised by the EPIC study.

Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K; EPIC Study Group.

BJU Int. 2008 Jun;101(11):1381-7. doi: 10.1111/j.1464-410X.2008.07573.x. Epub 2008 Mar 10.

17.

The challenge of overactive bladder therapy: alternative to antimuscarinic agents.

Lazzeri M, Spinelli M.

Int Braz J Urol. 2006 Nov-Dec;32(6):620-30. Review.

18.

Overactive bladder.

Kavia R, Mumtaz F.

J R Soc Promot Health. 2005 Jul;125(4):176-9. Review.

PMID:
16094929
19.

Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women.

Teleman PM, Lidfeldt J, Nerbrand C, Samsioe G, Mattiasson A; WHILA study group.

BJOG. 2004 Jun;111(6):600-4.

20.

Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer?

Boettcher M, Haselhuhn A, Jakse G, Brehmer B, Kirschner-Hermanns R.

BJU Int. 2012 Jun;109(12):1824-30. doi: 10.1111/j.1464-410X.2011.10623.x. Epub 2011 Sep 27.

Supplemental Content

Support Center